<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02328014</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-LY-001</org_study_id>
    <nct_id>NCT02328014</nct_id>
  </id_info>
  <brief_title>Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies</brief_title>
  <official_title>A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and
      efficacy acalabrutinib and ACP 319 in B-cell malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events from the combination of acalabrutinib and ACP-319</measure>
    <time_frame>From first dose of study drug until 30 days after last dose of study drugs</time_frame>
    <description>To characterize the safety profile of acalabrutinib and ACP-319 in subjects with relapsed or refractory B-cell malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration (AUC)</measure>
    <time_frame>4 Cycles (1 Cycle = 28 days)</time_frame>
    <description>Characterize the Pharmacokinetic parameter AUC of acalabrutinib and ACP-319</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>4 Cycles (1 Cycle = 28 days)</time_frame>
    <description>Characterize the Pharmacokinetic parameter Cmax of acalabrutinib and ACP-319</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Pharmacodynamic (PD) effects</measure>
    <time_frame>2 Cycles (1 cycle = 28 days) and at end of treatment</time_frame>
    <description>To evaluate the concentration pharmacodynamic effects of acalabrutinib and ACP-319</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Activity of acalabrutinib and ACP-319</measure>
    <time_frame>From enrollment to the date of disease progression, assessed up to 36 Cycles (1 cycle is 28 days)</time_frame>
    <description>To evaluate the activity of acalabrutinib as measured by overall response rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Non-hodgkins Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>B-All</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The acalabrutinib dose will be fixed and the ACP-319 dose will be escalated in each of three cohorts, and each cohort will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion groups of up to 12 subjects for Germinal center B-cell (GCB) DLBCL and Non-GCB DLBCL to take a fixed dose of acalabrutinib and ACP-319. Each disease group will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Expansion</arm_group_label>
    <other_name>ACP-196</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACP-319</intervention_name>
    <description>Oral</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Diagnosis of a b-cell malignancy as documented by medical records and with histology
             based on criteria established by the World Health Organization (WHO).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 2.

          -  Agreement to use contraception during the study and for 90 days after the last dose of
             study drugs if sexually active and able to bear or beget children.

        Exclusion Criteria

          -  A life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of study drugs, or put the study outcomes at undue risk.

          -  Central nervous system (CNS) involvement by lymphoma/leukemia

          -  Any therapeutic antibody within 4 weeks of first dose of study drugs.

          -  The time from the last dose of the most recent chemotherapy or experimental therapy to
             the first dose of study drugs is &lt; 5 times the half-life of the previously
             administered agent(s).

          -  ANC &lt; 0.5 x 10^9/L or platelet count &lt; 50 x 10^9/L unless due to disease involvement
             in the bone marrow.

          -  Creatinine &gt; 1.5 x institutional upper limit of normal (ULN); total bilirubin &gt; 1.5 x
             ULN (unless due to Gilbert's disease); and aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) &gt; 3.0 x ULN.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Acerta Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2014</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton tyrosine kinase inhibitor</keyword>
  <keyword>Btk</keyword>
  <keyword>B-Cell Malignancies</keyword>
  <keyword>Mantle Cell</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Follicular</keyword>
  <keyword>Waldenstrom</keyword>
  <keyword>B-All</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

